We believe that the referred SAR and drug-likeness considerations discussed in this review for chalcones with p53–MDM2 inhibitory effect can pave the way for rational design of new p53–MDM2 inhibitors, leading to accelerate the discovery of more efficient anti-cancer drug candidates in the near future. The gene discussed is TP53; the disease is cancer.